_________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

11th–12th February 2021


 

Add to calendar



Approved in principle

 

Agenda

Please note the final agenda may be subject to change.

Day 1: Thursday 11 February

12:00 – 12:15 Welcome to Masterclass 2021: Opening address
12:15 – 13:30 Session 1: Immune Thrombocytopenia (ITP)
  The American Society of Hematology and International Consensus Guidelines for ITP
  Adult ITP registry in the UK – what have we learnt?
13:30 – 13:45 Break
13:45 – 14:45 Session 2: Chronic Myeloid Leukaemia (CML)
  TARGET-CML study: Data from real-world evidence
  The Management of CML in 2021
14:45 – 15:00 Break
15:00 – 16:00 Session 3: Acute Myeloid Leukaemia (AML)
  An overview of minimal residual disease in AML
  Exploring the clinincal utility of minimal residual disease to support treatment decisions
16:00 – 16:15 Break
16:15 – 17:15 Session 4: Myelofibrosis (MF)
  The value of early intervention in MF
  Difficult scenarios and challenging cases in MF
17:15 Day close

Day 2: Friday 12 February

11:45 – 12:00 Welcome to Masterclass 2021: Day 2
12:00 – 13:30 Session 5: Myelodysplastic Syndrome (MDS) and Iron Overload (IOL)
  Mechanisms of IOL in MDS
  Impact of iron in MDS: Defining the problem
  IOL monitoring and management in MDS
  MDS in the clinic – a case study
13:30 – 13:45 Break
13:45 – 14:45 Session 6: Sickle Cell Disease
  New service configuration in SCD across the UK
  An update on the SCD treatment landscape: A case-based approach
14:45 – 15:00 Break
15:00 – 16:30 Session 7: CAR-T Cell Therapy in the Management of Lymphoma
  Third-line treatment of diffuse large B-cell lymphoma
  CAR-T cell therapy referral – who, when, how?
  Long-term outcomes of CAR-T cell therapy
16:30 – 16:40 Virtual meeting close

Novartis’ Haematology Masterclass has historically been a two-day face-to-face meeting that aims to support healthcare professionals with a special interest in haematology to share the latest thinking and trial data within the field. By sharing this critical information, the meeting will help to support the implementation of best clinical practice with a focus on the future of patient care within some of the most challenging haematological disorders.

Due to COVID-19 and the current social distancing measures in the UK, Haematology Masterclass 2021 will be hosted virtually.

The event will run from 11th–12th February 2021. 

Heritage

Haematology Masterclass has been running for the past six years and continues to deliver the most up-to-date and thought-provoking data in the field of haematology. Since 2014, the meeting has brought presentations from leading specialists in the UK and globally.

Our promise

Novartis is truly committed to providing world-class education to our UK healthcare professionals. We recognise the value this meeting brings to a vast range of physicians including registrars, nurses, pharmacists and consultants. We hope that you can join us for our next meeting in 2021.

This meeting is funded and organised by Novartis Pharmaceuticals Ltd. and is classed as promotional under the Association of the British Pharmaceutical Industry (ABPI) Code.
The prescribing information for the Novartis brands mentioned during this event will be available at this meeting.

UK | January 2021 | 103320
×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at http://www.report.novartis.com/
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]